Previous close | 10.00 |
Open | 5.90 |
Bid | 4.70 |
Ask | 5.30 |
Strike | 70.00 |
Expiry date | 2024-08-16 |
Day's range | 5.40 - 5.90 |
Contract range | N/A |
Volume | |
Open interest | 362 |
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Intra-Cellular Therapies (ITCI) and Zentalis Pharmaceuticals, Inc. (ZNTL) are in the spotlight following pipeline and regulatory updates, respectively.
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.